Physician profile
Kirk K Peterson
NPI 1255391983
$576,061.69
in general payments reported to CMS, 2019-2025
33 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $67K · 2021: $70K · 2022: $91K · 2023: $71K · 2024: $107K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $280K · Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $280,091.25 |
| Food and Beverage | $255.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $505,034.96 | 2020-2025 | |
| Shire North American Group INC | $66,194.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $597.43 | 2019-2021 | |
| Novo Nordisk INC | $488.33 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.44 | 2019-2022 | |
| Amgen INC. | $396.06 | 2019-2023 | Prolia, Evenity |
| Allergan, INC. | $388.51 | 2019-2020 | |
| Abbvie INC. | $376.43 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $328.88 | 2019-2023 | Xigduo |
| Glaxosmithkline, LLC. | $327.28 | 2019-2023 | Shingrix |
| Biohaven Pharmaceutical Holding Company Ltd. | $180.84 | 2022 | |
| Pfizer INC. | $166.22 | 2019-2023 | |
| Abbott Laboratories | $134.98 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $125.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $122.33 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $104.48 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.68 | 2019-2021 | |
| Stryker Corporation | $62.55 | 2021 | |
| Celgene Corporation | $59.06 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.78 | 2021-2022 | |
| Lilly USA, LLC | $49.87 | 2019-2023 | Emgality, Jardiance |
| Idorsia Pharmaceuticals US INC | $47.38 | 2022-2023 | Quviviq |
| Therapeuticsmd, INC. | $47.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $38.91 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.60 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $27.64 | 2020 | |
| Genentech USA, INC. | $20.19 | 2020 | |
| Kaleo, INC. | $19.99 | 2022 | |
| Pacira Therapeutics, INC. | $19.63 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.27 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.57 | 2019 | |
| Amarin Pharma, INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.